AVANT TECHNOLOGIES Business Summary

Avaí Bio, Inc. (formerly Avant Technologies Inc., OTCQB: AVAI) is an emerging biotechnology firm specializing in the development of cell-based therapies for type 1 and insulin-dependent type 2 diabetes, age-related disorders, and healthy longevity. The company operates through a partnership-driven business model, generating revenue primarily through licensing agreements and strategic joint ventures, most notably Insulinova, Inc. and Klothonova, Inc. Its core technological advantage lies in the integration of genetically modified cellular platforms with proprietary encapsulation technology, which aims to deliver therapeutic proteins like insulin and α-Klotho while shielding cells from immune rejection without the need for immunosuppressive drugs. In the competitive landscape of regenerative medicine and longevity biotech, Avaí Bio competes with larger players such as MannKind (MNKD), Altimmune (ALT), and Lineage Cell Therapeutics (LCTX), positioning itself as a micro-cap innovator focused on scalable, clinical-grade delivery systems for metabolic and age-related therapies. The company is currently led by Chief Executive Officer Chris Winter, who assumed the role in November 2024 following a tenure as COO; he brings over 35 years of experience in investment banking and commodities to the firm's strategic pivot. The executive team includes Chief Financial Officer and Treasurer Vitalis Racius, who also serves as a Director, and Chief Information Security Officer Danny Rittman, who oversees the integration of AI-enhanced cybersecurity within the company's healthcare data infrastructure. Scientific advancement is supported by key collaborators such as Dr. Eva Maria Lilli Brandtner, who leads the evaluation of advanced cell lines for the company’s diabetes programs. Founded in 2017 and headquartered in Las Vegas, Nevada, the company has recently transitioned from its legacy in AI computing infrastructure to a pure-play biotechnology focus, supported by a board that includes Corporate Secretary Natalija Tunevic and Director Ivan Lunegov.